NICE Approves New Cancer and PAH Drugs for NHS Use, Impacting Patient Treatment Options
The UK National Institute for Health and Care Excellence (NICE) has approved the use of AstraZeneca's Imfinzi and MSD's Winrevair for the National Health Service (NHS) in England. Imfinzi, an immunotherapy drug, is now recommended for use in treating an aggressive form of stomach cancer, specifically gastric and gastro-oesophageal junction (GEJ) cancer. This approval follows the drug's recent authorization by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for use in a pre- and post-surgery regimen. Clinical trials have shown that Imfinzi, when used in combination with chemotherapy, can significantly delay cancer recurrence and extend patient survival. Meanwhile, Winrevair, a first-in-class ActRIIA-Fc fusion protein, has been approved as an add-on therapy for pulmonary arterial hypertension (PAH), a severe form of pulmonary hypertension. This drug aims to improve exercise capacity in patients and represents a significant advancement in PAH treatment. 
